Rhythm Pharmaceuticals Past Earnings Performance
Past criteria checks 0/6
Rhythm Pharmaceuticals's earnings have been declining at an average annual rate of -18.2%, while the Biotechs industry saw earnings growing at 22.1% annually. Revenues have been growing at an average rate of 77.3% per year.
Key information
-18.2%
Earnings growth rate
-6.7%
EPS growth rate
| Biotechs Industry Growth | 17.0% |
| Revenue growth rate | 77.3% |
| Return on equity | -169.6% |
| Net Margin | -232.4% |
| Last Earnings Update | 30 Sep 2024 |
Recent past performance updates
Recent updates
Rhythm Pharmaceuticals: A Key Year Ahead
Dec 06Is Rhythm Pharmaceuticals (NASDAQ:RYTM) Using Debt Sensibly?
Sep 23
Rhythm: Upcoming sNDA Label Expansion IMCIVREE Isn't The Only Catalyst On Deck
Sep 22Rhythm: Pivotal Moment Approaching In Hypothalamic Obesity (Rating Upgrade)
Aug 29Rhythm: Navigating Imcivree's Potential In Rare Obesity Treatments (Rating Upgrade)
Jun 12Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Just Reported And Analysts Have Been Cutting Their Estimates
May 09Rhythm Pharmaceuticals, Inc.'s (NASDAQ:RYTM) Shares May Have Run Too Fast Too Soon
May 05Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Released Earnings Last Week And Analysts Lifted Their Price Target To US$57.22
Mar 03Rhythm Pharmaceuticals: Action Too Specific
Feb 23Subdued Growth No Barrier To Rhythm Pharmaceuticals, Inc.'s (NASDAQ:RYTM) Price
Jan 08We're Hopeful That Rhythm Pharmaceuticals (NASDAQ:RYTM) Will Use Its Cash Wisely
Nov 03We're Not Very Worried About Rhythm Pharmaceuticals' (NASDAQ:RYTM) Cash Burn Rate
Jul 23Rhythm Pharmaceuticals, Inc.'s (NASDAQ:RYTM) Popularity With Investors Is Under Threat From Overpricing
Jun 17Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Just Reported And Analysts Have Been Cutting Their Estimates
May 05Rhythm Pharmaceuticals (NASDAQ:RYTM) Is In A Good Position To Deliver On Growth Plans
Apr 01An Intrinsic Calculation For Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Suggests It's 46% Undervalued
Dec 15We Think Rhythm Pharmaceuticals (NASDAQ:RYTM) Needs To Drive Business Growth Carefully
Oct 24Rhythm Pharmaceuticals: Revisiting The Investment Thesis
Oct 10Rhythm Pharmaceuticals announces $100M stock offering; shares fall 12% after hours
Sep 14Rhythm Pharma's Imcivree drug gets expanded approval by European Commission for BBS
Sep 06Industry Analysts Just Made An Incredible Upgrade To Their Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Revenue Forecasts
Aug 08Rhythm Pharmaceuticals Q2 2022 Earnings Preview
Aug 01Rhythm Pharma gains as NICE recommends obesity drug
Jul 18Revenue & Expenses Breakdown
How Rhythm Pharmaceuticals makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 24 | 113 | -262 | 139 | 227 |
| 30 Jun 24 | 102 | -261 | 134 | 222 |
| 31 Mar 24 | 92 | -274 | 127 | 226 |
| 31 Dec 23 | 77 | -185 | 118 | 135 |
| 30 Sep 23 | 62 | -186 | 111 | 129 |
| 30 Jun 23 | 44 | -182 | 103 | 116 |
| 31 Mar 23 | 34 | -181 | 95 | 114 |
| 31 Dec 22 | 24 | -181 | 92 | 109 |
| 30 Sep 22 | 17 | -181 | 87 | 117 |
| 30 Jun 22 | 13 | -176 | 82 | 123 |
| 31 Mar 22 | 5 | -166 | 75 | 117 |
| 31 Dec 21 | 3 | -70 | 68 | 104 |
| 30 Sep 21 | 1 | -62 | 61 | 95 |
| 30 Jun 21 | 0 | -60 | 54 | 90 |
| 31 Mar 21 | 0 | -56 | 48 | 88 |
| 31 Dec 20 | 0 | -134 | 46 | 90 |
| 30 Sep 20 | 0 | -132 | 42 | 93 |
| 30 Jun 20 | 0 | -134 | 42 | 97 |
| 31 Mar 20 | 0 | -146 | 42 | 109 |
| 31 Dec 19 | 0 | -141 | 37 | 109 |
| 30 Sep 19 | 0 | -133 | 36 | 103 |
| 30 Jun 19 | 0 | -115 | 34 | 88 |
| 31 Mar 19 | 0 | -87 | 31 | 61 |
| 31 Dec 18 | 0 | -74 | 28 | 50 |
| 30 Sep 18 | 0 | -59 | 24 | 38 |
| 30 Jun 18 | 0 | -53 | 18 | 33 |
| 31 Mar 18 | 0 | -47 | 13 | 30 |
| 31 Dec 17 | 0 | -38 | 10 | 23 |
| 30 Sep 17 | 0 | -36 | 8 | 22 |
| 30 Jun 17 | 0 | -32 | 7 | 21 |
| 31 Mar 17 | 0 | -30 | 6 | 21 |
| 31 Dec 16 | 0 | -29 | 6 | 20 |
| 30 Sep 16 | 0 | -27 | 6 | 18 |
| 30 Jun 16 | 0 | -23 | 6 | 14 |
| 31 Mar 16 | 0 | -17 | 5 | 10 |
| 31 Dec 15 | 0 | -12 | 3 | 7 |
| 30 Sep 15 | 0 | -6 | 2 | 4 |
| 30 Jun 15 | 0 | -3 | 1 | 2 |
| 31 Mar 15 | 0 | -5 | 1 | 4 |
| 31 Dec 14 | 0 | -6 | 1 | 5 |
Quality Earnings: RYTM is currently unprofitable.
Growing Profit Margin: RYTM is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: RYTM is unprofitable, and losses have increased over the past 5 years at a rate of 18.2% per year.
Accelerating Growth: Unable to compare RYTM's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: RYTM is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (16.6%).
Return on Equity
High ROE: RYTM has a negative Return on Equity (-169.58%), as it is currently unprofitable.
Return on Assets
Return on Capital Employed
Discover strong past performing companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/20 23:54 |
| End of Day Share Price | 2024/12/20 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Rhythm Pharmaceuticals, Inc. is covered by 16 analysts. 11 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Tazeen Ahmad | BofA Global Research |
| Whitney Ijem | Canaccord Genuity |
| Corinne Johnson | Goldman Sachs |